Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda entities : Curis, inc. save search
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID
Published: 2023-07-06 (Crawled : 12:00) - prnewswire.com
CRIS | $14.6 2.03% 1.99% 21K
|
Health Technology
|
| O: -8.58%
H: 18.67%
C: 12.55%
fda leukemia study
FDA Partially Clears Curis Leukema Trial in Second August Regulatory Win - Updated
Published: 2022-08-30 (Crawled : 15:20) - biospace.com/
CRIS | $14.6 2.03% 1.99% 21K
|
Health Technology
|
| O: -5.36%
H: 2.83%
C: -4.72%
fda trial
FDA Partially Clears Curis Leukema Trial in Second August Regulatory Win - Up...
Published: 2022-08-30 (Crawled : 15:20) - biospace.com/
CRIS | $14.6 2.03% 1.99% 21K
|
Health Technology
|
| O: -5.36%
H: 2.83%
C: -4.72%
fda trial
FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study
Published: 2022-08-30 (Crawled : 13:00) - biospace.com/
CRIS | $14.6 2.03% 1.99% 21K
|
Health Technology
|
| O: -5.36%
H: 2.83%
C: -4.72%
fda leukemia study
Curis Stock Soars after FDA Lifts Partial Hold on Lymphoma Trial
Published: 2022-08-18 (Crawled : 20:00) - biospace.com/
CRIS | $14.6 2.03% 1.99% 21K
|
Health Technology
|
| O: 64.76%
H: 2.31%
C: -27.17%
fda trial
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
Published: 2022-08-18 (Crawled : 13:00) - biospace.com/
CRIS | $14.6 2.03% 1.99% 21K
|
Health Technology
|
| O: 64.76%
H: 2.31%
C: -27.17%
fda study clinical hold
Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)
Published: 2022-04-11 (Crawled : 16:00) - biospace.com/
CRIS | $14.6 2.03% 1.99% 21K
|
Health Technology
|
| O: -4.17%
H: 4.35%
C: -4.35%
ca-4948 fda clinical hold
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Published: 2021-04-19 (Crawled : 13:00) - biospace.com/
CRIS | $14.6 2.03% 1.99% 21K
|
Health Technology
|
| O: -2.52%
H: 1.7%
C: -7.95%
treatment fda drug ca-4948 designation aml
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.